Vaginal seeding

BIOLOGICAL4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Peking University, Vanderbilt University Medical Center

Conditions

Allergic DiseasesAllergyAsthmaC-sectionCesarean Delivery Affecting NewbornGastrointestinal MicrobiomeHost Microbial InteractionsIntestinal Microbiome

Early Phase 1

Vaginal Microbiome Exposure and Immune Responses in C-section Infants

Active, not recruitingNCT03567707

National Institute of Allergy and Infectious Diseases (NIAID)Allergic Diseases, Asthma

Start: 2018-11-28End: 2027-01-31Updated: 2025-11-05

MOdification Of THe Early-Life Respiratory Microbiome Through Vaginal SEEDing

RecruitingNCT05505110

Vanderbilt University Medical CenterC-section, Microbiome, Respiratory +1

Start: 2022-11-09End: 2028-08-10Target: 20Updated: 2025-11-10

Phase 1

Vaginal Microbiome Seeding and Health Outcomes in Cesarean-delivered Neonates.

RecruitingNCT03298334

National Institute of Allergy and Infectious Diseases (NIAID)Cesarean Delivery Affecting Newborn, Gastrointestinal Microbiome, Host Microbial Interactions +3

Start: 2018-07-01End: 2029-04-30Target: 600Updated: 2025-06-08

Unknown Phase

Effects of Vaginal Seeding on Infants' Body Mass Index and Allergy Risk for Caesarean-delivered Children

Peking UniversityAllergy, Overweight and Obesity

Start: 2018-11-17End: 2022-11-30Updated: 2021-12-10

Related Papers

Protocol design for the ACTIVATE clinical trial: Exposure to vaginal microbiome in cesarean-delivered infants at high risk for allergies.

2025-08-20